Latest Commercialisation Strategy News

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.

Zoono Group reports expanding global trials of its shelf-life extension technology, engaging over 40 supermarket and packaging companies, while refining its product and managing cash flow amid cautious commercial adoption.

Hazer Group has successfully completed its Commercial Demonstration Plant program ahead of schedule, validating its methane pyrolysis technology and securing significant funding to accelerate commercialisation in 2025.

Livium and Mineral Resources have agreed to extend their joint development agreement, funding additional optimisation activities for the LieNA® lithium extraction technology and setting the stage for a 50/50 joint venture.